COVID-19 is a contagious disease caused by the Severe Acute Respiratory Syndrome Corona Virus-2, a single-stranded RNA genome. After its initial occurrence in, in November, 2019, in Wuhan, China, it has resulted in a worldwide pandemic. In India since early 2020 over 1,05,42,000 have been infected and over 1,52,000 have succumbed to it. A year after the first recorded case in India, the immunisation exercise against the disease kicked off on 16^th January, 2021, with two vaccines: Covishield and Covaxin. Serum Institute of India in Covidhield has grafted the COVID-19 antigen onto an adenovirus. On the other hand the ICMR-Bharat Biotech candidate called Covaxin, is based on inactivated virus and represents a tried and tested technology. Despite the last-stage trial still being in progress, Bharat Biotech has also been given emergency use authorization [1].

References

1. Shayak B and Sharma MM. “COVID-19 Spreading Dynamics with Vaccination-Allocation Strategy, Return to Normalcy and Vaccine Hesitancy”. medRxiv (2020): 12.10.20247049.
2. MacDonald NE. “Vaccine hesitancy: Definition, scope and determinants”. Vaccine34 (2015): 4161-4164.
3. Bhopal S and Nielsen M. “Vaccine hesitancy in low-and middle-income countries: potential implications for the COVID-19 response”. Archives of Disease in Childhood 106 (2020): 113-114.

Citation

Citation: Suprakash Chaudhury.“COVID 19 Vaccine Hesitancy”. Acta Scientific Neurology 4.3 (2021): 01-02.

Copyright

Copyright: © 2021 Suprakash Chaudhury. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.